What is DA Davidson’s Estimate for PBH Q3 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – DA Davidson issued their Q3 2025 EPS estimates for Prestige Consumer Healthcare in a report released on Monday, November 11th. DA Davidson analyst L. Weiser forecasts that the company will post earnings of $1.16 per share for the quarter. DA Davidson currently has a “Buy” rating and a $95.00 target price on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare’s FY2025 earnings at $4.46 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The firm had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same period in the previous year, the company posted $1.07 EPS. The company’s revenue for the quarter was down .9% on a year-over-year basis.

Separately, Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.20.

Prestige Consumer Healthcare Trading Down 0.0 %

Shares of Prestige Consumer Healthcare stock opened at $81.71 on Tuesday. The company has a market capitalization of $4.04 billion, a P/E ratio of 19.88, a price-to-earnings-growth ratio of 2.27 and a beta of 0.47. The stock has a fifty day simple moving average of $72.69 and a 200 day simple moving average of $69.92. Prestige Consumer Healthcare has a 12-month low of $56.61 and a 12-month high of $82.82. The company has a current ratio of 3.56, a quick ratio of 1.90 and a debt-to-equity ratio of 0.61.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new position in shares of Prestige Consumer Healthcare during the 1st quarter valued at approximately $428,000. Texas Permanent School Fund Corp increased its position in Prestige Consumer Healthcare by 1.4% in the first quarter. Texas Permanent School Fund Corp now owns 43,452 shares of the company’s stock worth $3,153,000 after buying an additional 588 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Prestige Consumer Healthcare during the 1st quarter valued at $218,000. Swiss National Bank grew its stake in shares of Prestige Consumer Healthcare by 0.3% during the 1st quarter. Swiss National Bank now owns 97,900 shares of the company’s stock worth $7,104,000 after acquiring an additional 300 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Prestige Consumer Healthcare in the 1st quarter worth about $55,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.